Aurinia Pharmaceuticals Aktie
WKN DE: A1W7D4 / ISIN: CA05156V1022
28.08.2024 12:00:00
|
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the H.C. Wainwright 26th Annual Global Investment Conference in New York City, September 9-11, 2024.
Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 10, at 10:30 AM EST. This session will not include a webcast.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, and its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828651786/en/

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Aurinia Pharmaceuticals Incmehr Nachrichten
06.11.24 |
Ausblick: Aurinia Pharmaceuticals vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu Aurinia Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
Aurinia Pharmaceuticals Inc | 6,96 | 2,62% |
|